Prosecution Insights
Prosecution Insights
30 pending office actions • 24 art units • 30 examiners • 0 of 30 (0%) have an AI response strategy ready • 50 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (10%) |
| §103 only | 9 (30%) |
| §112 only | 5 (17%) |
| Double-patenting only | 2 (7%) |
| Double-patenting + other | 3 (10%) |
| Multi-statute (no §101) | 7 (23%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIEDEMAN, JASON S | 1 | 28.7% | +35.1% |
| TSAY, MARSHA M | 1 | 45.7% | +52.5% |
| VAN BUREN, LAUREN K | 1 | 39.5% | +58.0% |
| MIDDLETON, DANAYA L | 1 | 46.1% | +54.1% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 76.6% | +34.8% |
| NGUYEN, QUANG | 1 | 38.1% | +53.0% |
| GODDARD, LAURA B | 1 | 51.0% | +14.0% |
| TCHERKASSKAYA, OLGA V | 1 | 55.2% | +46.3% |
| HANEY, AMANDA MARIE | 1 | 36.5% | +44.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007433 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | SZNAIDMAN, MARCOS L | 37d overdue |
| 18299640 | USE OF AN IRAK4 MODULATOR FOR GENE THERAPY | KOSAR, ANDREW D | 8d |
| 18315316 | FLOW CYTOMETRY ATTENUATED REPORTER EXPRESSION (FLARE) MULTIPLE REPORTER SYSTEM AND METHODS OF USE THEREOF | PARISI, JESSICA DANIELLE | 46d |
| 18407298 | RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT CONDITIONS IN MAMMALS | NGUYEN, QUANG | 86d |
| 19128502 | Machine Learning Systems and Methods to Identify Locations of Potential Patients and/or Healthcare Providers | TIEDEMAN, JASON S | — |
| 18626784 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | — |
| 18389951 | ANTI-PD-1×4-1BB BINDING PROTEINS | GODDARD, LAURA B | — |
| 18515897 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | TCHERKASSKAYA, OLGA V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18644528 | HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | MIDDLETON, DANAYA L | 13d |
| 18407298 | RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT CONDITIONS IN MAMMALS | NGUYEN, QUANG | 86d |
| 19128502 | Machine Learning Systems and Methods to Identify Locations of Potential Patients and/or Healthcare Providers | TIEDEMAN, JASON S | — |
| 18817164 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances | TSAY, MARSHA M | — |
| 18648199 | METHODS OF IMPROVING RAAV PRODUCTION | VAN BUREN, LAUREN K | — |
| 18593643 | INDOLE COMPOUNDS AND METHODS OF USE | HEASLEY, MEGHAN CHRISTINE | — |
| 18389951 | ANTI-PD-1×4-1BB BINDING PROTEINS | GODDARD, LAURA B | — |
| 18515897 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1628 | 2 |
| 3683 | 1 |
| 1674 | 1 |
| 1626 | 1 |
| 1615 | 1 |
| 1682 | 1 |
| 1797 | 1 |
| 1641 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19128502 | Machine Learning Systems and Methods to Identify Locations of Potential Patients and/or Healthcare Providers | TIEDEMAN, JASON S | 3683 | §101§103§112 | Non-Final OA | — | Pending | May 08, 2025 |
| 18817164 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances | TSAY, MARSHA M | — | §112DP | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18648199 | METHODS OF IMPROVING RAAV PRODUCTION | VAN BUREN, LAUREN K | — | §103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18644528 | HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §112 | Final Rejection | 13d | Pending | Apr 24, 2024 |
| 18626784 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | — | DP | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18593643 | INDOLE COMPOUNDS AND METHODS OF USE | HEASLEY, MEGHAN CHRISTINE | 1626 | §112 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18407298 | RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT CONDITIONS IN MAMMALS | NGUYEN, QUANG | 1631 | §103§112 | Non-Final OA | 86d | Pending | Jan 08, 2024 |
| 18389951 | ANTI-PD-1×4-1BB BINDING PROTEINS | GODDARD, LAURA B | — | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18515897 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Final Rejection | — | Pending | Nov 21, 2023 |
| 18560569 | NOVEL PREDICTIVE BIOMARKERS FOR SECONDARY AUTOIMMUNITY AFTER LYMPHOCYTE DEPLETING THERAPY | HANEY, AMANDA MARIE | 1682 | §101§102§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18470507 | METHODS FOR QUANTIFYING DRUG CONCENTRATION IN A PRODRUG COMPOSITION | ADAMS, MICHELLE | 1797 | DP | Final Rejection | — | Pending | Sep 20, 2023 |
| 18463047 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18331748 | Treatment of Hemophilia with Fitusiran | INAM, SAHAR | 1622 | §102§103 | Non-Final OA | — | Pending | Jun 08, 2023 |
| 18256199 | TREATMENT OF HEMOPHILIA WITH FITUSIRAN | FAN, LYNN Y | 1759 | §103 | Non-Final OA | — | Pending | Jun 06, 2023 |
| 18319279 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | PUTTLITZ, KARL J | 1646 | §103§112DP | Non-Final OA | — | Pending | May 17, 2023 |
| 18317772 | METHODS OF TREATING METACHROMATIC LEUKODYSTROPHY | SHIBUYA, MARK LANCE | 1631 | §103Other | Non-Final OA | 37d overdue | Pending | May 15, 2023 |
| 18315316 | FLOW CYTOMETRY ATTENUATED REPORTER EXPRESSION (FLARE) MULTIPLE REPORTER SYSTEM AND METHODS OF USE THEREOF | PARISI, JESSICA DANIELLE | 1684 | §101§102§103§112 | Non-Final OA | 46d | Pending | May 10, 2023 |
| 18141128 | INDUCTION OF IMMUNE TOLERANCE BY USING METHOTREXATE | LEE, CHIHYI NMN | 1628 | §112DP | Final Rejection | — | Pending | Apr 28, 2023 |
| 18299640 | USE OF AN IRAK4 MODULATOR FOR GENE THERAPY | KOSAR, ANDREW D | 1625 | §103§112Other | Non-Final OA | 8d | Pending | Apr 12, 2023 |
| 18186731 | Pharmaceutical Recombinant Human Acid Sphingomyelinase Compositions and Methods | IANNUZO, NATALIE NMN | 1653 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2023 |
| 18007433 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | SZNAIDMAN, MARCOS L | 1628 | §102§103§112 | Final Rejection | 37d overdue | Pending | Jan 30, 2023 |
| 18155655 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | SHIN, DANA H | 1635 | §112Other | Final Rejection | — | Pending | Jan 17, 2023 |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 26d | Pending | Oct 12, 2022 |
| 17721003 | METHODS OF PERFUSION CULTURING A MAMMALIAN CELL | LEVIN, JOEL D | 1633 | §103 | Non-Final OA | 74d overdue | Pending | Apr 14, 2022 |
| 17675474 | DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY | CRUM, MARY ABOU NADER | 1657 | Other | Non-Final OA | — | Pending | Feb 18, 2022 |
| 17375785 | METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103Other | Final Rejection | 54d | Pending | Jul 14, 2021 |
| 17104593 | PHARMACEUTICAL COMPOSITIONS FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY | FERNANDEZ, SUSAN EMILY | 1651 | §103 | Final Rejection | — | Pending | Nov 25, 2020 |
| 16807102 | METHODS FOR TREATING PROTEINOPATHIES | RODRIGUEZ-GARCIA, VALERIE | 1621 | §103 | Final Rejection | 15d overdue | Pending | Mar 02, 2020 |
| 16088031 | BIOMARKERS OF PROTEOPATHIES AND USES THEREOF | FONTAINHAS, AURORA M | 1675 | §103 | Final Rejection | 35d | Pending | Sep 24, 2018 |
| 14004377 | PEGYLATED APELIN AND USES THEREOF | KOMATSU, LI N | 1658 | §103 | Non-Final OA | 44d overdue | Pending | Feb 10, 2014 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial